Stoke Therapeutics(STOK)

BEDFORD, MABiotechnology1 H-1B visas (FY2023)

Focus: Stoke Therapeutics is a public biotech company specializing in antisense oligonucleotide (ASO) medicines for gene therapy, with a focused pipeline in rare neurological disorders. The company is early-stage commercial with FY2025 revenue of $37M and significant R&D investment.

Gene Therapy

Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

12-4 this month

Stable — net -4 jobs in 30d

4 added, 8 removed. Backfill posture.

Should You Work at Stoke Therapeutics?

AI assessment

A high-risk, high-science bet for technologists and clinical researchers betting on ASO platform success; less suitable for commercial or operations professionals seeking stable near-term growth.

Why Work Here

Lead role in cutting-edge antisense technology platform with multiple programs advancing (zorevunersen in Phase 2/3 for Dravet Syndrome, STK-001 in Phase 1/2)

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$37M

Key Products

zorevunersen

Dravet Syndrome

Development

Lead proprietary program in Phase 2/3 development; primary catalyst for company value and proof-of-concept for ASO platform in pediatric epilepsy.

Pipeline & Clinical Trials

Help build intelligence for Stoke Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides equity upside and operational stability without late-stage biotech cash burn constraints

Strong R&D focus (244% intensity) signals commitment to science-driven advancement and career development in novel modalities

Watch Out For

Rapid cash burn ($89M R&D vs. $37M revenue) combined with declining cash position ($128M in FY2025 vs. $191M in FY2024) raises funding sustainability concerns
Limited clinical success signals—no Phase 4 commercial wins, only 1 Phase 3 program (zorevunersen), and pipeline includes repurposed/non-proprietary assets (Pethidine, Milrinone), suggesting execution risk

Generated by Claude from Stoke Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Experimental: Device Intervention

Spinal Cord Injuries

N/A

Clinical Trials (1)

NCT05615766Assessment of a Robotic Exoskeleton for Upper Limb Rehabilitation

N/A

STK-001 - Single Ascending Doses

Dravet Syndrome

PHASE_1_2

Clinical Trials (1)

NCT04442295An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

Phase 1/2

zorevunersen

Dravet Syndrome

PHASE_2

Clinical Trials (1)

NCT04740476An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

Phase 2

Milrinone

Valvular Stenosis

PHASE_2

Clinical Trials (1)

NCT00819377Milrinone Inhaled in Cardiac Surgery

Phase 2

zorevunersen

Dravet Syndrome

PHASE_3

Clinical Trials (1)

NCT06872125A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Phase 3

Pethidine

Pain Relief in Labour

PHASE_4

Clinical Trials (1)

NCT02179294A Randomised Controlled Trial of Remifentanil Intravenous Patient Controlled Analgesia (PCA) Versus Intramuscular Pethidine for Pain Relief in Labour

Phase 4

Transanal irrigation with Peristeen Anal Irrigation

Constipation

PHASE_4

Interview Prep Quick Facts

Founded: 2014

Portfolio: 6 clinical trials

Top TAs: Cardiovascular

H-1B (2023): 1 approval

Publications: 18 in PubMed

SEC Filings: 2 available

Open Roles: 12 active jobs

Therapeutic Area Focus

Cardiovascular

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$37M316%

R&D Spend

$89M(244%)8%

Net Income

-$89M

Hiring Trend

Stable

Open Roles

Added

-1

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Private Funding (SEC Form D)

Nov 2018

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Zorevunersen in Children and Adolescents with Dravet Syndrome.

The New England journal of medicine

2026

PMID:41780062

Generation of four human pluripotent stem cell lines harboring OPA1-related optic atrophy variant.

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Stoke Therapeutics(STOK)

Should You Work at Stoke Therapeutics?

Why Work Here

Key Products

Pipeline & Clinical Trials

Watch Out For

Recent News · Stoke Therapeutics(10)

Open Jobs (12)

Associate Director, Consumer Marketing

Senior Manager, Corporate Affairs

Director, Global Regulatory Affairs

Senior Director, Corporate Quality

Pharmacovigilance Scientist

Director, Strategic Purchasing

Director, Financial Planning & Analysis (R&D)

Senior Director, Global Medical Information & Operations

Associate Director, HCP Marketing

Senior Director, Clinical Quality Compliance

Sr. Medical Director, Pharmacovigilance

Vice President, Field Leader, Market Access Field National & Regional

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Private Funding (SEC Form D)

Research Publications(10)